Literature DB >> 19956173

From pathogenesis to treatment of chronic lymphocytic leukaemia.

Thorsten Zenz1, Daniel Mertens, Ralf Küppers, Hartmut Döhner, Stephan Stilgenbauer.   

Abstract

Chronic lymphocytic leukaemia (CLL) has several unique features that distinguish it from other cancers. Most CLL tumour cells are inert and arrested in G0/G1 of the cell cycle and there is only a small proliferative compartment; however, the progressive accumulation of malignant cells will ultimately lead to symptomatic disease. Pathogenic mechanisms have been elucidated that involve multiple external (for example, microenvironmental stimuli and antigenic drive) and internal (genetic and epigenetic) events that are crucial in the transformation, progression and evolution of CLL. Our growing understanding of CLL biology is allowing the translation of targets and biological classifiers into clinical practice.

Entities:  

Mesh:

Year:  2009        PMID: 19956173     DOI: 10.1038/nrc2764

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  149 in total

1.  Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Authors:  Emanuela M Ghia; Sonia Jain; George F Widhopf; Laura Z Rassenti; Michael J Keating; William G Wierda; John G Gribben; Jennifer R Brown; Kanti R Rai; John C Byrd; Neil E Kay; Andrew W Greaves; Thomas J Kipps
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

Review 2.  The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia.

Authors:  Thomas J Kipps
Journal:  Best Pract Res Clin Haematol       Date:  2007-09       Impact factor: 3.020

Review 3.  Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?

Authors:  Federico Caligaris-Cappio; Paolo Ghia
Journal:  J Clin Oncol       Date:  2008-07-28       Impact factor: 44.544

4.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

5.  Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Authors:  G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

6.  Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

Authors:  J C Byrd; C Shinn; R Ravi; C R Willis; J K Waselenko; I W Flinn; N A Dawson; M R Grever
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

7.  Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

Authors:  Gerard Tobin; Ulf Thunberg; Anna Johnson; Inger Eriksson; Ola Söderberg; Karin Karlsson; Mats Merup; Gunnar Juliusson; Juhani Vilpo; Gunilla Enblad; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

8.  Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.

Authors:  Andy C Rawstron; Martin R Yuille; Julie Fuller; Matthew Cullen; Ben Kennedy; Stephen J Richards; Andrew S Jack; Estella Matutes; Daniel Catovsky; Peter Hillmen; Richard S Houlston
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

Authors:  Fiona Murray; Nikos Darzentas; Anastasia Hadzidimitriou; Gerard Tobin; Myriam Boudjogra; Cristina Scielzo; Nikolaos Laoutaris; Karin Karlsson; Fanny Baran-Marzsak; Athanasios Tsaftaris; Carol Moreno; Achilles Anagnostopoulos; Federico Caligaris-Cappio; Dominique Vaur; Christos Ouzounis; Chrysoula Belessi; Paolo Ghia; Fred Davi; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

10.  Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology.

Authors:  Graça M Dores; William F Anderson; Rochelle E Curtis; Ola Landgren; Evgenia Ostroumova; Elizabeth C Bluhm; Charles S Rabkin; Susan S Devesa; Martha S Linet
Journal:  Br J Haematol       Date:  2007-10-17       Impact factor: 6.998

View more
  206 in total

1.  [Chronic lymphocytic leukemia: current standards and novel approaches].

Authors:  E Tausch; S Stilgenbauer
Journal:  Internist (Berl)       Date:  2014-12       Impact factor: 0.743

Review 2.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

3.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

4.  Chronic lymphocytic leukemia--genomics lead the way.

Authors:  Daniel Mertens; Lars Bullinger; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

5.  Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

6.  Ofatumumab.

Authors:  Michael J Keating; Argyris Dritselis; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

Review 7.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

8.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

9.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

10.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Authors:  Alan G Ramsay; Rachel Evans; Shahryar Kiaii; Lena Svensson; Nancy Hogg; John G Gribben
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.